ClinicalTrials.gg
CompletedNCT03651765Updated May 31, 2025Results posted

Long Term Extension Trial of Setmelanotide

A Phase 2/3 interventional study of Setmelanotide in Obesity Associated With Defects in Leptin-melanocortin Pathway, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 27 sites in 8 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
205
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.

Enrollment
3rd of 16
205 · median 34
Started
2018
with 2 others
Phase 2/3
Only one
of the 16
Registered
9th of 16
by date
Lead sponsor
15 of 16
Rhythm Pharmaceuticals, Inc.

Among the 16 studies testing setmelanotide in Obesity, this one is the 3rd largest by enrollment, is one of 3 that started in 2018, is the only one in phase 2/3, and was the 9th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About setmelanotide

setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing setmelanotide in Obesity, or all of them as a file.
02

Study summary

This was a long-term extension trial to study the safety and tolerability of continued setmelanotide treatment in participants who had completed a previous clinical trial on treatment with setmelanotide for obesity associated with genetic defects upstream of the Melanocortin-4 (MC4) receptor in the leptin-melanocortin pathway.

Read the detailed description

The primary objectives of this extension trial were to explore the long-term safety and tolerability of setmelanotide for up to 7 years or until drug was otherwise available through authorized use. Participants entered this protocol immediately upon completion of their index protocol such that dosing of setmelanotide continued without gaps in therapy.

03

Conditions studied

  • Obesity Associated With Defects in Leptin-melanocortin Pathway

Browse trials for

Keywords

  • setmelanotide
  • RM-493
  • obesity
  • leptin-melanocortin
  • melanocortin 4 receptor
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants aged 2 or older (or aged >2 years as per local regulations) who had completed participation in a previous setmelanotide trial and demonstrated adequate safety and meaningful clinical benefit (efficacy)
  2. Participant and/or parent or guardian was able to communicate with the investigator, understand and sign the written /assent, and comply with the trial requirements
  3. Agree to use a highly effective form of throughout the trial

Key Exclusion Criteria:

  1. Pregnant and/or breastfeeding women
  2. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)
  3. Current, disease
  4. Documented diagnosis of schizophrenia, bipolar disorder, personality disorder, major depressive disorder, or other psychiatric disorder(s)
  5. Suicidal ideation, attempt or behavior
  6. History of significant liver disease
  7. Moderate to severe renal dysfunction as defined by a (GFR)\<30 milliliters per minute (mL/min).
  8. History or close family history of melanoma or participant history of oculocutaneous albinism

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
205 participants (actual)

Study arms

  • Experimental
    Setmelanotide

    Participants received setmelanotide at the same starting dose as received in the index trials as a Subcutaneous (SC) injection once daily for up to 5.6 years in this extension trial.

    Drug: Setmelanotide

Interventions

  • Once daily subcutaneous injection

    Also known as: RM-493

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE was defined as any AE that began or worsened in intensity on or after the date of the first administration of study drug.

    Time frame: From first dose up to 5.6 years

07

Results

Posted May 31, 2025

Participant flow

Participants from previous index trials (RM-493-011\[NCT02507492\], RM-493-012 \[NCT02896192\], RM-493-014\[NCT03013543\], RM-493-015 \[NCT03287960\], RM-493-023 \[NCT03746522\], RM-493-030 \[NCT04725240\], RM-493-034 \[NCT04963231\] with rare genetic, syndromic, or acquired diseases of obesity upstream of the Melanocortin-4 receptor (MC4R) in the melanocortin-leptin pathway and other abnormalities of the MC4R pathway and wished to continue with setmelanotide treatment were enrolled in this extension trial.

Participant flow — Overall Study
MilestoneSetmelanotide
Started205
Completed89
Not completed116
Withdrew: Adverse event6
Withdrew: Lack of efficacy18
Withdrew: Lost to follow-up5
Withdrew: Non-compliance with study drug4
Withdrew: Physician decision6
Withdrew: Pregnancy1
Withdrew: Discontinued by sponsor40
Withdrew: Withdrawal by parent/guardian6
Withdrew: Withdrawal by subject24
Withdrew: Miscellaneous6

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE was defined as any AE that began or worsened in intensity on or after the date of the first administration of study drug.

Time frame:
From first dose up to 5.6 years
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsSetmelanotide
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)198

Adverse events

Collected over From first dose up to 5.6 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Setmelanotide0/205 (0%)27/205 (13.2%)198/205 (96.6%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventSetmelanotide
Adrenocortical insufficiency acuteEndocrine disorders3/205
Suicidal ideationPsychiatric disorders2/205
SeizureNervous system disorders2/205
CraniopharyngiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/205
Endometrial cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps)1/205
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/205
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/205
Renal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/205
Gastroenteritis Escherichia coliInfections and infestations1/205
Pilonidal diseaseInfections and infestations1/205
Most frequent other events
Showing 10 of 617
Most frequent other events
EventSetmelanotide
Skin HyperpigmentationSkin and subcutaneous tissue disorders110/205
Covid-19Infections and infestations60/205
HeadacheNervous system disorders60/205
Injection Site ErythemaGeneral disorders43/205
Melanocytic NaevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)41/205
Injection Site PruritusGeneral disorders38/205
Upper Respiratory Tract InfectionInfections and infestations36/205
Injection Site IndurationGeneral disorders35/205
NasopharyngitisInfections and infestations32/205
NauseaGastrointestinal disorders28/205

Baseline characteristics

Safety Analysis Set (SAS) included all participants who received at least one dose of received at least 1 dose of setmelanotide in this extension trial.

Age, Continuous
Age, Continuous(Years)Setmelanotide
Mean22.7 ± 14.93
Sex: Female, Male
Sex: Female, Male(Participants)Setmelanotide
Female125
Male80
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Setmelanotide
American Indian or Alaska Native3
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American10
White167
More than one race0
Unknown or Not Reported24
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Setmelanotide
Hispanic or Latino10
Not Hispanic or Latino171
Unknown or Not Reported24
08

Study locations

27 sites
  • Synexus Clinical Research US, Inc. - Phoenix Southeast
    Chandler, Arizona 85224, United States
  • Honor Health Research Institute
    Scottsdale, Arizona 85258, United States
  • San Diego Wake Research
    San Diego, California 92108, United States
  • University of Florida College of Medicine
    Gainesville, Florida 32610, United States
  • Baystate Medical Center
    Springfield, Massachusetts 01107, United States
  • University at Buffalo
    Buffalo, New York 14203, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Wake Research
    Raleigh, North Carolina 27612, United States
  • Obesity Institute, Geisinger Clinic
    Danville, Pennsylvania 17822-2607, United States
  • Childrens Hospital of Philadephia
    Philadelphia, Pennsylvania 19104, United States
  • Synexus Clinical Research US, Inc.- Primary Care Associates, PC
    Anderson, South Carolina 29621, United States
  • Wake Research TN
    Chattanooga, Tennessee 37421, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
  • Seattle Children's Research Institute
    Seattle, Washington 98101, United States
  • Marshfield Clinic Research Institute
    Marshfield, Wisconsin 54449, United States
  • University of Alberta
    Edmonton, Alberta T6G 2E1, Canada
  • Hôpital Trousseau
    Paris, 75012, France
  • Hôpital de la Pitié Salpêtrière
    Paris, 75013, France
  • Charité - Universitätsmedizin Berlin
    Berlin, 13354, Germany
  • University of Leipzig
    Leipzig, 04103, Germany
  • University of Ulm
    Ulm, 89075, Germany
  • University General Hospital of Patras
    Rio, 26504, Greece
  • Erasmus MC
    Rotterdam, Netherlands
  • Universidad Autónoma de Madrid
    Madrid, 65 28009, Spain
  • University Hospitals Birmingham NHS Foundation Trust
    Birmingham, B15 2GW, United Kingdom
  • Wellcome Trust-MRC Institute of Metabolic Science
    Cambridge, CB2 0QQ, United Kingdom
  • Hammersmith Hospital
    London, W12 0NN, United Kingdom
09

References and documents

Publications

  • Roth CL, Scimia C, Shoemaker AH, Gottschalk M, Miller J, Yuan G, Malhotra S, Abuzzahab MJ. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol. 2024 Jun;12(6):380-389. doi: 10.1016/S2213-8587(24)00087-1. Epub 2024 Apr 30. PubMed 38697184 ↗
  • Meyer JR, Krentz AD, Berg RL, Richardson JG, Pomeroy J, Hebbring SJ, Haws RM. Kidney failure in Bardet-Biedl syndrome. Clin Genet. 2022 Apr;101(4):429-441. doi: 10.1111/cge.14119. PubMed 35112343 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jan 2025, 77 months.

Results were first posted in May 2025, 4 months after primary completion.

Of 36 phase 2/3 interventional studies under Obesity, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 53. This study's 77 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2018
First posted
Aug 29, 2018
StartActual
Jul 15, 2018
Primary completionActual
Jan 9, 2025
CompletionActual
Jan 9, 2025
Results first posted
May 31, 2025
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03651765
Responsible party
Sponsor
First posted
Aug 29, 2018
Start date
Jul 15, 2018
Primary completion
Jan 9, 2025
Completion
Jan 9, 2025
Results posted
May 31, 2025
Last update
May 31, 2025

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion